EXACT Sciences Announces Additions to Senior Management; New Hires Add Depth and Strength to Company's Management Team.Business Editors and Health/Medical Writers BIOWIRE2K MAYNARD, Mass.--(BW HealthWire)--July 19, 2001 EXACT Sciences Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :EXAS) announced today that it has added three new members to its senior management team. Joining EXACT Sciences are Stephen Read, Vice President and Controller, David Nikka, Vice President of Resources and Development, and William Pignato, Vice President of Regulatory Affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas: All of the positions are new within the company and reflect the movement of EXACT Sciences from a development stage business to a company with commercial operations. Prior to joining EXACT, Mr. Read was Vice President and Corporate Controller for Renaissance Worldwide and Concentra Managed Care. Mr. Nikka joins EXACT from ABIOMED, a medical device company where he held the position of Vice President, Human Resources The fancy word for "people." The human resources department within an organization, years ago known as the "personnel department," manages the administrative aspects of the employees. . Mr. Pignato most recently worked as the Director of Regulatory Affairs at Bayer Diagnostics, and prior to that, Director of Regulatory Affairs at Chiron Diagnostics Corporation. "These appointments virtually complete the management team that EXACT Sciences needs to emerge as a company with both commercial and research operations," stated Don Hardison, EXACT Sciences' President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "Steve, Dave and Bill have had successful careers at some of the leading companies in their fields and bring a wealth of knowledge and experience to EXACT Sciences. We are delighted to welcome them on board at this exciting time in our history." About EXACT Sciences Corporation EXACT Sciences Corporation is an applied genomics applied genomics Molecular genetics Molecular medicine The use of genetic information to diagnose, prognosticate and manage disease, based on the techniques of PCR, real time-PCR, DNA sequencing, and gene rearrangement studies for leukemia and lymphoma. company that has developed proprietary technologies that may be used for the early detection of several common cancers. EXACT Sciences has selected colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. as the first application of its technologies. Colorectal cancer is the most deadly cancer among non-smokers, and is curable cur·a·ble adj. Capable of being cured or healed. if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, the Years, The the seven decades of Eleanor Pargiter’s life. [Br. Lit.: Benét, 1109] See : Time rate of early detection of colorectal cancer remains low. EXACT Sciences believes its genomics-based technologies will enable early detection of colorectal cancer so that more people can be effectively treated. Founded in 1995, EXACT Sciences is based in Maynard, Mass. Detailed information on EXACT Sciences can be found on the World Wide Web at www.exactsciences.com. Information on EXACT Sciences also is available at 866-IR4-EXAS. This press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to a variety of risks and uncertainties, many of which are beyond EXACT Sciences' control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, that EXACT Sciences is a development stage company that has no commercial product and no expectation of material revenue until 2003. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. EXACT Sciences undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks faced by EXACT Sciences, see the disclosure contained in EXACT Sciences' public filings with the Securities and Exchange Commission including, without limitation, its Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2000 and subsequent Forms 10-Q. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion